Variable-frequency electric field generation system and application thereof in pathological angiogenesis treatment

Through the variable frequency electric field generation system in the treatment of pathological angiogenesis, the alternating electric field is used to inhibit the generation of pro-angiogenesis factors, solving the problem of poor efficacy in the prior art and achieving a safe and non-invasive angiogenesis inhibition effect.

CN119015600AActive Publication Date: 2024-11-26XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +1
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202410723010.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-05
Publication Date
2024-11-26
Estimated Expiration
2044-06-05

AI Technical Summary

Technical Problem

The prior art has poor efficacy in treating pathological angiogenesis, especially for deep, widely dispersed, malignant pathological angiogenesis. The existing methods are unsatisfied with the efficacy of the existing methods and have high-risk systemic adverse reactions.

Method used

Using a variable frequency electric field generation system, an alternating power generator generates a sine wave signal of 500-1500kHz, and a flexible insulating electrode plate forms an alternating electric field at the lesion site, inhibiting the generation of pro-vascular growth factors, and realizing pathological angiogenesis. inhibition.

Benefits of technology

This method is non-invasive and safe, has the advantages of local application, avoids systemic adverse reactions, significantly inhibits pathological angiogenesis, and has broad application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015600A_ABST
    Figure CN119015600A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medical instruments, in particular to a variable-frequency electric field generation system and application thereof in pathological angiogenesis therapy, and the variable-frequency electric field generation system comprises an alternating power supply generator which is used for generating a sine wave signal, the frequency of the sine wave signal is 500-1500 kHz, and the amplitude of the sine wave signal is 50-100 Vpp; the first end of the wire is connected to the output end of the alternating power source generator. According to the invention, the medium-high frequency alternating electric field is generated to inhibit the generation of angiogenesis promoting factors at the diseased region, and the effect of inhibiting pathological angiogenesis is better. Compared with the prior art (such as bevacizumab, injection hardener, endovascular interventional embolism, surgical resection, radiotherapy, hormone therapy and the like), the device inhibits pathological angiogenesis through the alternating electric field, and has the advantages of noninvasive (body surface use) or minimally invasive (in vivo implantation), safety, local application, no systemic adverse reaction, pure physical property, no pollution and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medical devices, and in particular to a variable frequency electric field generating system and its application in the treatment of pathological angiogenesis. Background Art

[0002] Under physiological conditions, blood vessels are responsible for transporting blood, nutrients, and oxygen to organs and tissues throughout the body, while also taking away carbon dioxide and metabolic waste from tissues. Otherwise, organs and tissues will suffer from ischemia and hypoxia and die. Therefore, angiogenesis is essential for all organs throughout the body. During embryonic development and childhood growth, the angiogenesis process of all organs is very active. After adulthood, the blood vessels of most organs are in a dormant state, and endothelial cells generally divide only once every seven years. In the adult body, only when organs are damaged and repaired will the angiogenesis process be activated again to participate in tissue repair.

[0003] Angiogenesis refers to the growth of new microvessels from existing vascular networks. The process of angiogenesis includes degradation of vascular basement membrane; activation, proliferation, and migration of endothelial cells; and reconstruction of new blood vessels. The angiogenesis process is regulated by a variety of angiogenic growth factors and angiogenic inhibitors. Currently, a variety of angiogenic growth factors have been discovered, including VEGF, bFGF, IGF-1, TNF-α, TNF-β, and PDGF.

[0004] Pathological angiogenesis refers to abnormally active angiogenesis (angiogenesis) that is not physiologically required, which is a common pathological mechanism of many diseases. For example:

[0005] (1) Skin hemangioma: It is a benign tumor with capillary proliferation and dilation. It usually occurs shortly after birth, grows rapidly in infancy, then continues to grow with age, and stops developing in adulthood. Most of them invade the skin of the head and neck, seriously affecting the appearance. Clinically, it is divided into four types: port-wine stains, simple hemangiomas, cavernous hemangiomas, and mixed hemangiomas. Current treatments include surgical resection, external radiation therapy, isotope therapy, cryotherapy, laser therapy, sclerotherapy injection, hormone therapy, etc., which often require a combination of multiple methods. Large maxillofacial hemangiomas can also erode bones and require transcatheter arterial embolization or surgical resection, which is very risky.

[0006] (2) Retinal hemangioma: In the early stage, small hemangiomas or tangled capillaries appear in the peripheral part of the fundus. The affected retinal arteries and veins are dilated and tortuous. The capillaries at the junction of the arteries and veins are highly dilated to form spherical hemangiomas, which then gradually increase in size. There is localized retinal edema and exudation near the hemangioma, which may be accompanied by small hemorrhages. Due to leakage from the hemangioma wall, the surface of the tumor and the surrounding retina appear grayish white and turbid. As the disease progresses, the water in the exudate is absorbed, lipids are deposited, and large ring-shaped or arc-shaped yellow-white hard exudates appear around the hemangioma. When the exudate affects the macula, vision is significantly impaired. As the hemangioma continues to grow, the exudate also gradually increases, and the retina undergoes exudative detachment. In the late stage, it can cause blindness. Treatment methods include photocoagulation, cryotherapy, and diathermy electrocoagulation to shrink the hemangioma and turn it into a scar, but the effect is not good for large hemangiomas and often causes blindness.

[0007] (3) Cerebral proliferative angiopathy (CPA): It is manifested by diffuse, highly dense vascular network tissue on imaging, with normal brain tissue intermixed between abnormally proliferating cerebral blood vessels. It often affects the entire cerebral hemisphere or multiple lobes. Clinical manifestations include epilepsy, headache, progressive neurological deficits, including limb movement disorders, language disorders, mental disorders, etc. Some patients present with cerebral hemorrhage, with a rebleeding rate as high as 67%. Existing treatments include symptomatic treatment (such as anti-epileptic, analgesic), interventional intravascular embolization, indirect angioplasty and radiosurgery, but it is difficult to cure clinically.

[0008] (4) Cerebral arteriovenous malformation (AVM): It manifests as a malformed vascular mass with mixed arteries and veins, with thick supply arteries and drainage veins, and extremely large blood flow, which often leads to cerebral hemorrhage and epilepsy. Clinically, if the supply arteries and drainage veins are cut off, but the vascular mass is not completely removed, the remaining vascular mass will grow rapidly and re-establish the supply arteries and drainage veins, leading to recurrence. This process reflects vigorous pathological angiogenesis. Existing treatment options include intravascular interventional embolization therapy, surgical resection, and radiosurgery. The treatment effect of large or deep AVM is poor, often leading to cerebral hemorrhage and disability or death of patients; and the above-mentioned treatment methods themselves are also very risky, and massive bleeding, cerebral infarction or perfusion pressure breakthrough syndrome are prone to occur during the operation, which is life-threatening.

[0009] (5) Pathological angiogenesis of malignant tumors: Because malignant tumor tissue metabolism is very active, it requires more oxygen and nutrients than normal tissues, and also needs to eliminate metabolic products. The growth and survival of malignant tumors are highly dependent on pathological angiogenesis. When the diameter of the tumor is >2mm, it is no longer possible to obtain the required nutrients and oxygen by diffusion through the interstitial space alone. At this time, the local angiogenesis regulatory balance is broken, and many angiogenic growth factors, especially VEGF, are produced to promote tumor angiogenesis and provide material support for tumor growth, progression and metastasis. These new blood vessels provide nutrients for the continuously infiltrating and growing tumors. In turn, tumor cells secrete a variety of substances during their growth process to accelerate pathological angiogenesis of tumors. Due to the abnormal structure and function of the new blood vessels in tumor tissues and the imperfect vascular matrix, tumor cells can easily penetrate directly into the blood vessels, enter the bloodstream and metastasize to distant sites.

[0010] It should be noted that the treatment methods for tumors in the prior art also include electric field therapy. Although electric field therapy also loads an alternating electric field of a certain frequency to the lesion, the typical technical solution is shown in Patent Document 1, but its principle is to act on the tubulin of proliferating cancer cells through a low-intensity, medium-frequency (200kHz) alternating electric field, interfere with tumor cell mitosis, cause apoptosis of affected cancer cells and inhibit tumor growth, and does not have an anti-angiogenic therapeutic effect. On the one hand, the electric field frequency used in the present invention is different from that in Patent Document 1, so the biological effect is different (anti-cancer cell vs. anti-angiogenesis); on the other hand, more importantly, the target of the present invention is vascular endothelial cells, not tumor cells, and can be used not only for malignant tumor angiogenesis, but also for benign angiogenesis lesions.

[0011] Therefore, angiogenesis plays an important role in the development and metastasis of tumors, and inhibiting this process is beneficial to preventing tumor growth and spread and metastasis. At present, the treatment for this process generally uses anti-angiogenic drugs, including anti-vascular endothelial growth factor (VEGF) monoclonal antibodies, recombinant human endostatin, etc. In theory, anti-angiogenic drugs can inhibit the tumor angiogenesis process, degenerate existing tumor blood vessels, and thus slow down tumor growth. However, in actual applications, the efficacy of existing anti-angiogenic treatments for malignant tumors is still unsatisfactory, the survival benefits of patients are very low, and there are systemic adverse reactions such as gastrointestinal bleeding and perforation.

[0012] In summary, pathological angiogenesis is a common pathogenic mechanism of many diseases (including tumors and non-tumor diseases, benign and malignant, superficial and deep); accordingly, there are many treatment methods for pathological angiogenesis in clinical practice, and the treatment effect is good for superficial, benign, and small pathological angiogenesis, but the existing technology is not effective for deep, widely diffused, and malignant pathological angiogenesis, and the risks of some drugs and surgeries themselves are also high; therefore, there is an urgent need to develop new anti-angiogenesis treatment equipment.

[0013] Prior art literature:

[0014] Patent document 1CN112553075A A method and device for inhibiting the rapid growth of tumor cells using sensitive frequency electric fields Summary of the invention

[0015] In view of the technical problems existing in the prior art of anti-angiogenesis treatment, the first aspect of the present invention proposes a variable frequency electric field generating system, comprising:

[0016] An alternating power generator, the alternating power generator is used to generate a sine wave signal, the sine wave signal has a frequency of 500-1500kHz and an amplitude of 50-100Vpp;

[0017] A wire, a first end of which is connected to an output end of an alternating power generator;

[0018] at least one pair of insulated electrode plates connected to the second end of the wire;

[0019] The insulated electrode plate comprises a flexible conductive layer and a flexible insulating layer coated on both sides of the flexible conductive layer, and the insulated electrode plate is applied to the surface of the lesion site, or applied as an implant to the surface of the lesion internal organ;

[0020] When the alternating power generator outputs a sinusoidal wave signal to the insulating electrode plate, its rated output power is less than 3W, and the alternating electric field generated between a pair of the insulating electrode plates is used to inhibit the generation of angiogenic growth factors in the alternating electric field region.

[0021] Preferably, the distance between the pair of insulating electrode plates and the amplitude of the alternating power generator are configured to satisfy that the intensity of the alternating electric field generated between the pair of insulating electrode plates is greater than 0.6 V / cm.

[0022] Preferably, the flexible conductive layer comprises a metal layer, and the metal layer comprises a silver foil layer.

[0023] Preferably, the flexible insulating layer comprises an insulating film, and the insulating film comprises a polyimide film.

[0024] Preferably, the thickness of the flexible conductive layer and the flexible insulating layer is less than 0.1 mm.

[0025] Preferably, the frequency of the sinusoidal wave signal is 800-1200 kHz.

[0026] Preferably, the frequency of the sinusoidal wave signal is 1000 kHz.

[0027] Preferably, the alternating power generator includes a sine wave generator, a differential amplifier, a step-up transformer, a communication controller and a DC / DC isolated regulated power supply. The sine wave generator, the differential amplifier and the step-up transformer are connected in sequence, the communication controller is connected to the sine wave generator, and the DC / DC isolated regulated power supply provides power for each component.

[0028] Preferably, the sine wave generator adopts a high-frequency waveform generator of an integrated chip MAX038.

[0029] Preferably, the conductive wire comprises a coaxial wire.

[0030] The second aspect of the present invention proposes a technical solution, which is the application of the variable frequency electric field generating system as described above in the treatment of pathological angiogenesis.

[0031] Compared with the prior art, the advantages of the present invention are:

[0032] 1. Based on the research results of the inventor team's first discovery of alternating electric fields to inhibit pathological angiogenesis, the present invention inhibits the generation of angiogenic factors in the lesion by generating medium and high frequency alternating electric fields, and has a better effect on inhibiting pathological angiogenesis. Compared with the existing technologies (such as bevacizumab, injection sclerosing agents, intravascular interventional embolization, surgical resection, radiotherapy, hormone therapy, etc.), the device of the present invention inhibits pathological angiogenesis through alternating electric fields, and has the advantages of being non-invasive (surface use) or minimally invasive (implanted in the body), safe, locally applied, without systemic adverse reactions, and purely physical and pollution-free.

[0033] 2. The present invention designs the material of the insulating electrode plate, using a material with a soft texture and high electrical conductivity as the metal layer, and a material with a soft texture, good insulation performance, a large relative dielectric constant and good biocompatibility as the insulating layer, so that the insulating electrode plate has a soft texture as a whole and good adhesion, and can be conveniently and securely applied to the surface of the diseased part of the body or applied to the surface of the diseased organ as an in vivo implant.

[0034] 3. The present invention controls the alternating power generator to generate a sine wave signal with a frequency of 500-1500kHz, and the rated output power is less than 3W, which reduces the technical difficulty and implementation cost of the equipment on the one hand, and ensures the safety of the equipment on the other hand. The present invention can form high voltage and high field strength under normal use. In case the transmission wire or the electrode insulation layer is damaged, once the resistance is reduced, the voltage will instantly drop to an extremely low value, thereby avoiding the possibility of electric shock.

[0035] 4. The transmission wire of the present invention uses a coaxial line, which reduces voltage loss.

[0036] 5. Due to the design principle of extremely low output power of the alternating power generator, it is more energy-efficient, so the volume and weight of the storage battery used for power supply can be reduced, thereby increasing the portability of the device of the present invention.

[0037] 6. Pathological angiogenesis is a common pathogenic mechanism of many diseases (including tumors and non-tumor diseases, benign and malignant, superficial and deep), so the present invention has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] The drawings are not intended to be drawn to scale. In the drawings, each identical or nearly identical component shown in various figures may be represented by the same reference numeral. For clarity, not every component is labeled in every figure. Embodiments of various aspects of the present invention will now be described by way of example and with reference to the accompanying drawings, in which:

[0039] Figure 1 It is a structural schematic diagram of the variable frequency electric field generating system proposed by the present invention;

[0040] Figure 2 It is a structural schematic diagram of the alternating power source generator proposed by the present invention;

[0041] Figure 3 is a schematic cross-sectional view of an insulated electrode plate of the present invention;

[0042] Figure 4 This is a schematic diagram of the insulated electrode plate of the present invention in use on the body surface;

[0043] Figure 5 This is a schematic diagram of the insulated electrode plate of the present invention in use in vivo;

[0044] Figure 6 This is a schematic diagram of the experimental results shown in Example 1 of the present invention;

[0045] Figure 7 This is a schematic diagram of the experimental results shown in Example 2 of the present invention;

[0046] Figure 8is a schematic diagram of the experimental results shown in Example 3 of the present invention;

[0047] Fig. 9 is a schematic diagram of the experimental results shown in Example 4 of the present invention;

[0048] Fig.10 is a schematic diagram of the experimental results shown in Example 5 of the present invention;

[0049] Fig.11 is a schematic diagram of the experimental results shown in Example 6 of the present invention;

[0050] Fig.12 is a schematic diagram of the experimental results shown in Example 7 of the present invention;

[0051] Fig.13 is a schematic diagram of the experimental results shown in Example 7 of the present invention;

[0052] Fig.14 is a schematic diagram of the experimental results shown in Example 8 of the present invention;

[0053] Fig.15 is a schematic diagram of the experimental results shown in Example 9 of the present invention;

[0054] Fig.16 is a schematic diagram of the experimental results shown in Example 9 of the present invention;

[0055] Fig.17 is a physical schematic diagram of a TTFields unidirectional electric field generator shown in an embodiment of the present invention;

[0056] Fig.18 It is a diagram of the chicken embryo chorioallantoic membrane test and other animal test scenes shown in Example 1 of the present invention. DETAILED DESCRIPTION

[0057] In order to better understand the technical content of the present invention, specific embodiments are given and described as follows in conjunction with the accompanying drawings.

[0058] Combination Figure 1 and Fig.17 As shown, the first aspect of the present invention proposes a variable frequency electric field generating system, comprising an alternating power generator 100, a conductor 300 and at least one pair of insulated electrode plates 200, wherein the alternating power generator 100 is used to generate a sinusoidal wave signal, the sinusoidal wave signal has a frequency of 500-1500kHz and an amplitude of 50-100Vpp; the first end of the conductor 300 is connected to the output end of the alternating power generator 100; and the at least one pair of insulated electrode plates 200 is connected to the second end of the conductor 300.

[0059] The insulated electrode plate 200 includes a flexible conductive layer and a flexible insulating layer coated on both sides of the flexible conductive layer. The insulated electrode plate 200 is applied to the surface of the lesion site, or applied as an implant to the surface of the lesion internal organ.

[0060] When the alternating power generator 100 outputs a sine wave signal to the insulated electrode plate 200, its rated output power is less than 3W, and the alternating electric field generated between a pair of insulated electrode plates 200 is used to inhibit the generation of angiogenic factors in the alternating electric field region.

[0061] The alternating current generator 100 is used to generate a sine wave signal with a frequency of 500-1500kHz and an amplitude of 50-100Vpp to meet the individualized treatment needs of various diseased tissues, different parts and different patients.

[0062] Preferably, the spacing between the pair of insulated electrode plates 200 and the amplitude of the alternating power generator 100 are configured to satisfy the intensity of the alternating electric field generated between the pair of insulated electrode plates 200 to be greater than 0.6 V / cm. Under this electric field intensity, pathological angiogenesis is better inhibited, and it is safe and reliable to use.

[0063] Alternating power generator

[0064] like Figure 2 As shown, the alternating current power generator 100 of this embodiment includes a sine wave generator 1, a differential amplifier 2, a boost transformer 3, a communication controller 4 and a DC / DC isolated regulated power supply 5. The sine wave generator 1, the differential amplifier 2 and the boost transformer 3 are connected in sequence, the communication controller 4 is connected to the sine wave generator 1, and the DC / DC isolated regulated power supply 5 provides power for each component.

[0065] The sine wave generator is designed with a high-performance high-frequency waveform generator integrated chip MAX038, which has the ability to generate 0.1Hz~20MHz sine waves and can generate the 500-1500kHz sine wave signal required by this device with an amplitude of 2Vpp.

[0066] The differential amplifier 2 is responsible for amplifying the 500-1500kHz sine wave signal output by the sine wave generator. Since the signal frequency band is wide, the required output amplitude is large, which cannot be simply realized using an ordinary power amplifier circuit. For this reason, the present embodiment uses two wide-bandwidth amplifiers to amplify and output two signals with a positive and negative phase difference of 180 degrees. That is, two amplifiers are used to form a differential amplifier, each amplifier outputs a 25-50Vpp signal, and the two differentials generate a 50-100Vpp signal, thereby greatly reducing the requirements for the performance of a single amplifier.

[0067] In order to further reduce the requirements for amplifier performance, an output boost transformer is added to the output of the differential amplifier. By boosting the voltage with a transformer, an integrated operational amplifier with a lower supply voltage can be used to design a differential amplifier circuit, thereby ensuring stable boosting at higher frequencies and wider bandwidths.

[0068] The communication controller realizes the regulation and control of the output frequency and the output voltage, and controls the sine wave generator to output the required waveform.

[0069] The DC / DC isolated regulated power supply is responsible for converting the input 19-24V DC voltage into various voltages required by the machine, such as ±5V required by the sine wave generator and ±50V required by the wide-band amplifier.

[0070] The above-mentioned alternating current generator is connected to a pair of insulated electrode plates to generate an electric field; since the positive and negative electrodes are insulated, the resistance is extremely high and the current is extremely small (only <1μA leakage current), so the rated output power of the alternating current generator is designed to be <3W. The extremely low output power and high voltage of the alternating current are one of the characteristics of the present invention. On the one hand, it reduces the technical difficulty and implementation cost of the equipment, and on the other hand, it ensures the safety of the equipment: high voltage and high field strength can be formed under normal use. In case the transmission wire or the electrode insulation layer is damaged, once the resistance is reduced, the voltage will instantly drop to an extremely low value, thereby avoiding the possibility of electric shock.

[0071] In this embodiment, the wire 300 is a coaxial wire, which can reduce voltage loss.

[0072] Insulated electrode plate

[0073] like Figure 3 As shown, the insulated electrode plate 200 includes a sealed flexible insulating layer on both sides and a flexible conductive layer in the middle, that is, there is no gas or other medium remaining between the flexible insulating layer and the flexible conductive layer, and the flexible conductive layer is conductively connected to the wire 300. The outer surface of the flexible insulating layer is the surface of the insulated electrode plate in contact with the object to be acted on, which is used to form an alternating electric field in the area between a pair of insulated electrode plates.

[0074] Insulated electrode plates used for other electric field therapies in the current market generally use piezoelectric ceramics as the insulating layer. This is because piezoelectric ceramics have extremely high relative dielectric constants and dielectric strengths, which can reduce voltage loss and avoid high-voltage breakdown. However, piezoelectric ceramics are thick and hard, and poorly adhere to the skin, which can easily cause air gaps or skin damage, making them very inconvenient to use. Moreover, piezoelectric ceramics are difficult to implant into the body and can only be used on the body surface. Due to the safety of the extremely low-power alternating power supply of the present invention, the insulating layer of the insulated electrode plate does not need to be too thick, and an ultra-thin insulating layer can be used. In this embodiment, the thickness of the metal layer and the insulating layer are both less than or equal to 0.1 mm.

[0075] In an optional embodiment, the flexible conductive layer is made of a material with a soft texture and high conductivity, and the insulating layer is made of a material with a soft texture, good insulating performance, a large relative dielectric constant and good biocompatibility. The flexible conductive layer includes a metal layer 202, and the flexible insulating layer includes an insulating film 201. The metal layer can be made of silver foil, etc., and the insulating layer can be made of polyimide film, etc.

[0076] The dielectric strength of polyimide is 100-300KV / mm (reference: https: / / wenku.baidu.com / view / ed2ca4906037ee06eff9aef8941ea76e58fa4a28.html). When the thickness of the polyimide insulation layer is 0.05mm, it can prevent a voltage breakdown of 5000V, which is much higher than the peak voltage of 100V used in the present invention and is safe enough.

[0077] Since the insulating layer is very thin, the insulating layer does not need an ultra-high relative dielectric constant. The relative dielectric constant of the polyimide insulating layer is 3.4. According to the experimental electric field distribution calculation, the total voltage is 106V, the voltage distributed in the biological tissue reaches 84V (79.2%), and the voltage lost in the insulating layer is only 22V (20.8%). Since the insulating layer and the metal layer are very thin, the insulating electrode plate of the present invention is soft as a whole and has good adhesion, which is convenient for applying to the surface of the lesion part, or as an implant to the surface of the lesion internal organs, which is not available in the electric field treatment equipment in the prior art.

[0078] like Figure 4 The figure shows a schematic diagram of the insulated electrode plate 200 in use on the body surface, which is used for cerebral arteriovenous malformation. The insulated electrode plate 200 is applied to the surface of the skull, facing front and back, and connected to the alternating power generator 100 through a transmission wire 300. The lesion site is in the alternating electric field between the pair of insulated electrode plates.

[0079] like Figure 5 The figure shows a schematic diagram of the insulated electrode plate 200 in use in vivo. For liver cancer, the insulated electrode plate 200 is placed into the abdominal cavity as an implant through a surgical incision 400 and applied to the surface of the liver, and a transmission wire 300 is led out to connect with the alternating power generator 100.

[0080] The second aspect of the present invention proposes a technical solution, which is the application of the variable frequency electric field generating system as described above in the treatment of pathological angiogenesis.

[0081] The specific application implementation method is as follows: with the lesion site as the center, the insulating electrode plates of the electric field treatment device are applied to the body surface or the surface of the internal organs on both sides; the insulating electrode plates are connected to the alternating power generator through the transmission wire, so that an alternating electric field is formed in the area between the two electrode plates, and the electric field strength (E1) can be calculated according to the relative dielectric constant (∈2) of the insulating layer of the electrode plate, the thickness of the insulating layer (d2), the relative dielectric constant (∈1) of the human tissue, the thickness (d1) of the human tissue and the voltage (U), and the formula is as follows:

[0082]

[0083] According to experimental results, when the electric field strength is >0.6V / cm and the electric field frequency is greater than 100kHz, the alternating electric field begins to show the effect of inhibiting pathological angiogenesis. When the electric field frequency is 1000kHz, the alternating electric field has the strongest effect in inhibiting pathological angiogenesis.

[0084] Preferably, the frequency of the sine wave signal is 1000 kHz.

[0085] In an optional embodiment, the frequency of the sine wave signal is 800-1200 kHz.

[0086] The inhibitory effect of the above-mentioned electric field treatment device on vascular growth factor is verified in the following specific examples.

[0087] Example 1

[0088] This example uses a chicken embryo test to detect the effect of medium and high frequency alternating electric fields on pathological angiogenesis

[0089] Specifically, when primary blood vessels appear in chicken embryos, MCF-7 breast cancer cells are injected into the chicken embryos with a fine needle to stimulate pathological angiogenesis in the chicken embryos through tumor cells. Then a medium-high frequency alternating electric field is applied to the chicken embryos. The electric field strength of each electric field treatment group is 0.6V / cm, and the electric field frequency is 30, 50, 100, 200, 300, 500, 800, 1000, and 1500kHz, respectively. The control group does not receive electric field treatment. After 48 hours, the formation of secondary blood vessels in the chicken embryos is observed (the test scenario is as follows: Fig.18 As shown, the lower part is the chicken embryo chorioallantoic membrane test).

[0090] like Figure 6 As shown in the upper two columns, according to the experimental results of Example 1, it can be found that when the alternating electric field frequency is 1000kHz, the electric field has a significant inhibitory effect on angiogenesis.

[0091] Then, U87 glioma cells were used for verification. Figure 6As shown in the lower two columns, by comparing 200, 500, 1000, and 1500 kHz, it was also found that the 1000 kHz alternating electric field had the strongest inhibitory effect on angiogenesis.

[0092] Example 2

[0093] The purpose of this example is to detect the inhibitory effect of medium and high frequency alternating electric fields on the proliferation of vascular endothelial cells

[0094] As mentioned above, the process of angiogenesis includes the degradation of vascular basement membrane; the activation, proliferation and migration of vascular endothelial cells; the reconstruction of new blood vessels and vascular networks, in which vascular endothelial cells play the most important role; various angiogenic growth factors such as VEGF also play their role mainly by promoting the proliferation of vascular endothelial cells.

[0095] In order to study the mechanism by which high-frequency alternating electric fields inhibit angiogenesis, we used the CCK-8 (Cell Counting Kit-8) test to detect the inhibitory effect of electric fields on the proliferation of vascular endothelial cells.

[0096] The control group did not receive electric field treatment. The electric field strengths of the four electric field treatment groups were all 0.6 V / cm, and the electric field frequencies were 200, 500, 1000 kHz, and 1500 kHz, respectively. The electric field treatment was continued for 48 hours, and then the CCK-8 test was used to detect cell viability.

[0097] like Figure 7 As shown on the left, 200, 500 and 1500kHz electric fields slightly inhibit the proliferation of vascular endothelial cells, while 1000kHz electric field has a significant inhibitory effect, indicating that the alternating electric field achieves the effect of inhibiting angiogenesis by inhibiting the proliferation of vascular endothelial cells.

[0098] like Figure 7 As shown on the right, under the condition of selecting 1000kHz, the higher the electric field intensity, the stronger the inhibitory effect on vascular endothelial cell proliferation.

[0099] Combining the above-mentioned Embodiment 1 and Embodiment 2, it can be concluded that, compared with other frequencies, the inhibitory effect on the proliferation of vascular endothelial cells under the condition of 1000 kHz is better.

[0100] Example 3

[0101] Example 3 further experiments were conducted on vascular endothelial cells under 1000kHz electric field conditions. Through immunofluorescence chemical staining, it was found that the 1000kH alternating electric field caused the microtubules of vascular endothelial cells to show a "wool ball"-like change: Since the classical mechanism of TTFields involves mitotic inhibition, we tried to determine whether AEF (Alternating Electric Fields) induced HUVEC cell death by affecting the formation of spindles.

[0102] Combination Figure 8 The results shown show that treatment with AEF for 24 or 48 hours induced a distinct "thread ball"-like spindle structure, in stark contrast to the shuttle-like spindles observed in the control group.

[0103] It is noteworthy that the spindle structure induced by AEF is very similar to the spindle formed in vincristine, suggesting that there may be a common mode of action. It is known that vincristine is able to bind tubulin and hinder the polymerization of microtubule dimers, thereby preventing chromosome segregation in metaphase. These findings suggest that AEF exerts its inhibitory effect on HUVEC growth by interfering with the formation of general spindles. It is noteworthy that we did not observe abnormal behavior of chromosomes marked by histone H3 in the experimental groups.

[0104] Example 4

[0105] Example 4 further studied the inhibitory effect of 1000 kHz electric field on the growth of vascular endothelial cells, and found that two-photon imaging showed that 1000 kHz alternating electric field inhibited and reshaped animal tumor angiogenesis and produced a synergistic effect with bevacizumab.

[0106] Although tumor treating fields have achieved remarkable success in the treatment of glioblastoma, its anti-angiogenic effect in vivo has not been extensively studied. Based on the highly effective anti-angiogenic effect of AEF in chick embryo assay and tube formation assay, we established a glioblastoma mouse model (U87) to evaluate the anti-angiogenic effect of AEF in vivo (experimental scenarios such as Fig.18 As shown, the upper part is the mouse test scene).

[0107] Tumor-bearing mice were injected intratumorally (it) with PBS or bevacizumab, and AEF treatment was performed by adhering copper plate electrodes to the tumor surface. Bevacizumab is a first-line clinical treatment for anti-tumor angiogenesis, which provides an important reference for the anti-tumor angiogenesis effect of AEF.

[0108] One week after mouse tumors were treated, two-photon imaging was performed using Texas Red-labeled Dextran to observe the morphological characteristics of tumor vessels after bevacizumab or AEF treatment.

[0109] Combination Fig. 9 As shown, representative images of tumor vessels in our control (PBS), AEF, bevacizumab, and bevacizumab & AEF groups were analyzed. The vessels in the control group showed highly leaky, disorganized, dilated, and cystic features. In contrast, the vessels in the AEF, bevacizumab, and bevacizumab & AEF groups were significantly reduced.

[0110] Among them, bevacizumab treatment mainly eliminated large blood vessels and capillaries in the tumor microenvironment, but did not change the disordered morphology of tumor blood vessels. In contrast, AEF treatment effectively converted disordered blood vessels into parallel capillaries, similar to normal blood vessels found in skeletal muscle.

[0111] It was observed that the parallel capillaries were strictly perpendicular to the direction of the electric field delivered by AEF through two pairs of sensor arrays that generated perpendicular fields. Notably, most capillaries were broken into dozens of fragments. In addition, AEF and bevacizumab showed synergistic inhibition of glioblastoma angiogenesis, resulting in fewer blood vessels in the AEF&bevacizumab group.

[0112] To this end, we conclude that AEF reduces and remodels tumor vessels into parallel capillaries and enhances the antiangiogenic effect of bevacizumab.

[0113] Example 5

[0114] Example 5 continued to use other means to analyze the growth inhibition mechanism of blood vessels by 1000 kHz alternating electric field. Microvessel quantitative analysis showed that 1000 kHz alternating electric field significantly inhibited animal tumor angiogenesis.

[0115] Two-photon imaging allowed us to assess the number and diameter of blood vessels in each tumor sample section. Based on their diameter, the blood vessels were divided into three categories: "capillaries" (≤9 μM), "medium-sized vessels" (≥14 μM), and "large-sized vessels" (>14 μM).

[0116] Based on this, in order to comprehensively investigate the effect of AEF on angiogenesis, we performed quantitative analysis of tumor vasculature using two-photon imaging and 3D simulation diagrams.

[0117] exist Fig.10 The left column shows representative images of the surface, middle, and inner layers of tumors without treatment (Control) or after different treatments (AEF, bevacizumab, and AEF & bevacizumab).

[0118] Each two-photon imaging or simulation graph contains data from three independent mice (R1, R2, and R3), and the number of each type of vessel is listed above the graph points.

[0119] We observed that the number of blood vessels in the simulation graphs was generally consistent with the two-photon imaging results for all treatment groups, except for the control group. The leaky nature of tumor blood vessels in the control group resulted in the release of imaging agents into the surrounding microenvironment, generating a strong background that made it difficult for the analysis software to distinguish blood vessels from the background, especially capillaries. To further compare the average number of the three types of blood vessels between the control, AEF, and bevacizumab groups, we analyzed the data from two-photon imaging. The results showed significant differences between the groups.

[0120] AEF treatment resulted in a significant increase in the number of capillaries (37.33±2.52), which was significantly higher than that in the control group (23.33±7.23) and the bevacizumab group (17.0±7.21). On the other hand, the number of medium-sized vessels was significantly lower in the AEF group (2.3±1.5), compared with a higher number in the control group (22.0±8.66) and the bevacizumab group (17.0±5.29). Importantly, there were almost no large-sized vessels in the AEF group. In addition, the total number of vessels was significantly higher in the control group than in the AEF and bevacizumab group (two-photon imaging). In the AEF&bevacizumab group, there were no significant differences between the three types of vessels.

[0121] Therefore, the AEF group could significantly inhibit the growth of capillaries into medium and large blood vessels.

[0122] Example 6

[0123] 1000kHz alternating electric field inhibits tumor angiogenesis and tumor growth in animals.

[0124] Combination Fig.11 To further evaluate the effectiveness of AEF in inhibiting tumor growth, we extended the treatment period and used intravenous bevacizumab as a positive control, considering the standard drug administration in clinical cancer treatment. After 14 days of treatment, both AEF (0.42 ± 0.1 g) and bevacizumab (0.88 ± 0.39 g) significantly inhibited tumor growth.

[0125] Compared with the PBS group (1.31±0.33 g), it is noteworthy that AEF had an even higher inhibitory effect on tumor growth than bevacizumab. In addition, AEF demonstrated the ability to enhance the therapeutic effect of intravenous bevacizumab (0.045±0.026 g).

[0126] We believe that, in addition to the individual antiangiogenic effects of AEF and bevacizumab, their combined use resulted in a synergistic effect. This effect was at least partially attributed to AEF-induced normalization of tumor vasculature. This normalization facilitated efficient delivery of oxygen and bevacizumab to the tumor, thereby enhancing the overall therapeutic effect. These findings suggest that AEF effectively inhibits the growth of U87 tumors and produces a potent synergistic effect in combination with bevacizumab. This highlights the potential of AEF as an effective strategy for cancer treatment and provides a new avenue for improving anticancer therapy.

[0127] It can be concluded that AEF inhibits angiogenesis and subsequently promotes tumor shrinkage.

[0128] Example 7

[0129] Based on Example 5, two-photon microscopic imaging showed that all blood vessels within the tumor were transformed into a unique pattern, known as “parallel capillaries.” To further investigate the distribution and organization of these blood vessels, we performed immunohistochemistry on tumor samples.

[0130] Considering that the direction of the electric field is known to be strictly perpendicular to the coronal plane of the tumor, we obtained the coronal plane ( Fig.12 ) and cross section ( Fig.13 ) paraffin sections for immunohistochemical studies, such as Fig.12 This allowed us to closely study the arrangement of blood vessels in different planes and gain a comprehensive understanding of the effects of AEF on the tumor vascular network.

[0131] In the PBS group, the blood vessels in the middle and surface layers of the tumor appeared large, abundant, and randomly scattered without a uniform direction. Similarly, the morphology and distribution of the tumor blood vessels in the bevacizumab group did not differ significantly from those in the PBS group, although they were fewer and smaller, indicating the effective anti-angiogenic effect of the anticancer drug. In contrast, the AEF-treated group showed a completely different pattern. The blood vessels of the tumor were in a consistent direction with a discontinuous, dot-like structure, which was completely consistent with the results of two-photon imaging ( Fig.12 ).

[0132] In addition, the number of blood vessels in the surface and middle layers of the AEF group was significantly reduced compared with the PBS group. Importantly, tumor cells stained with DAPI and α-tubules did not show significant changes in the three groups, indicating that AEF mainly affected vascular endothelial cells rather than tumor cells. This observation was further confirmed by TUNEL experiments, which showed that bevacizumab induced apoptosis in tumor cells and vascular endothelial cells, while in the AEF group, apoptosis mainly occurred in vascular endothelial cells.

[0133] Overall, the two-photon microscopic imaging and immunohistochemistry results provide valuable insights into the effects of AEF on tumor vasculature. The vessels were arranged in a consistent orientation with a clear background after intravenous injection of fluorescently labeled Dextran, suggesting that AEF has the potential to reorganize tumor vasculature in addition to its antiangiogenic effects.

[0134] Example 8

[0135] Based on Example 5, we further confirmed this by TUNEL assay, which showed that bevacizumab induced apoptosis of tumor cells and vascular endothelial cells, and in the AEFs group, most apoptotic cells (green) overlapped with CD31-labeled vascular endothelial cells (red) ( Fig.14 A), which means that 1000kHz AEFs tend to induce apoptosis of vascular endothelial cells rather than tumor cells. By applying trend lines to connect the intermittent blood vessels, we generated a simulated image similar to two-photon imaging, in which the capillaries in the tumor are oriented perpendicular to the electric field direction ( Fig.14 B). In summary, two-photon imaging (Figure), immunohistochemistry results ( Fig.12 and 13 ) and TUNEL assays once again demonstrated that the present invention can reshape the intratumoral vascular structure and reduce angiogenesis.

[0136] Example 9

[0137] Based on Example 5, we conducted a comprehensive bioinformatics analysis of the transcriptome data of the control group and the AEFs-treated group tumors ( Fig.15 A). Volcano plot showing differential gene expression between the two groups revealed that 98 genes were upregulated and 101 genes were downregulated after AEFs treatment compared with the control group. Hierarchical clustering heat map analysis further highlighted the major differentially expressed genes ( Fig.15 B). Among the genes upregulated in the AEFs group, including myosin heavy chain (MYH) 1, MYH2, MYH4, MYH13, myosin-associated protein (NRAP) binding to actin, long noncoding RNA 2603 (LINC02603), tetraspanin 2 (TSPAN2), and actin-binding protein α2 (ACTN2), these genes are mainly related to muscle function and cell motility. The re-expression or upregulation of these genes is associated with muscle regeneration or injury, similar to the effect of chronic electrical stimulation. This may partly explain the phenomenon of parallel capillary formation in AEFs-treated tumors, which may involve cell movement in a specific direction. In addition, AEFs treatment led to a significant downregulation of chemokines (CXCL1, CXCL2, CXCL3, CXCL5, and CXCL8) and matrix metalloproteinases (MMP1, MMP3, and MMP12) ( Fig.15C). Notably, members of the CXC chemokine family, including CXCL1, CXCL2, CXCL3, CXCL5, and CXCL8, play an important role in promoting tumor angiogenesis by activating CXCR1 and CXCR2. Similarly, matrix metalloproteinases MMP1, MMP3, and MMP12 are key regulators of tumor angiogenesis, vascular structure, permeability, and integrity. Downregulation of these chemokines and matrix metalloproteinases contributes to the anti-angiogenic effect of AEFs. In addition, AEFs treatment reduced interleukin 6 (IL-6) levels, a characteristic of the tumor microenvironment that is able to promote tumorigenesis by regulating various cancer hallmarks and multiple signaling pathways, including proliferation, apoptosis, angiogenesis, and metastasis. The reduction in IL-6 levels indicates downregulation of cancer-related features and inhibition of tumor growth. However, other important angiogenesis-related factors, such as VEGF and HIF-1α, were not significantly different between the AEFs and control groups. This suggests that the anti-angiogenic effect of 1000kHz AEFs is VEGF-independent, making it a complementary therapy to bevacizumab. In addition, KEGG pathway analysis revealed significant changes in pathways with known anti-tumor and anti-angiogenic abilities, including MAPK, cytokine-cytokine receptor interactions, NOD-like receptors, chemokine signaling, and TNF signaling pathways ( Fig.15 D). Gene set enrichment analysis (GSEA) of tumor gene data showed that the MAPK signaling pathway, cytokine-cytokine receptor interaction, chemokine signaling pathway, and JAK STAT signaling pathway were downregulated in the AEFs group compared with the control group ( Fig.15 E) Downregulation of these signaling pathways supports the inhibitory effect of AEFs on tumor angiogenesis.

[0138] The major gene expression changes in tumors after AEF treatment were further confirmed by real-time fluorescence quantitative PCR and immunohistochemistry. The results showed that many key angiogenesis-related genes were downregulated in the AEFs group compared with the control group ( Fig.16 A). In particular, in the control group, the mRNA levels of CXCL1 (P = 0.0112), CXCL5 (P = 0.0039), and MMP12 (P = 0.041) were more than ten times higher than those in the AEFs group, while the expression of CXCL2 (P = 0.0091), CXCL3 (P = 0.0267), CXCL8 (P = 0.0463), and MMP1 (P = 0.0002) was more than twenty times higher in the control group. In addition, the mRNA levels of IL-6 (P = 0.0266) and MMP3 (P = 0.0336) in the AEFs group were significantly lower than those in the control group, decreasing by 61 and 71 times, respectively. Immunohistochemistry further verified the downregulation of these gene proteins ( Fig.16B). After AEFs treatment, CXCL1, CXCL2, and CXCL8 proteins were almost completely eliminated from the tumors. Although some residual proteins of CXCL3, CXCL5, MMP1, MMP3, and MMP12 were still detected, their levels were significantly reduced due to AEFs treatment. Collectively, these findings demonstrate that AEFs reduce the expression of angiogenesis-related chemokines and matrix metalloproteinases in glioblastoma tumors, thereby downregulating signaling pathways and inhibiting tumor angiogenesis.

[0139] Although the present invention has been disclosed as above with preferred embodiments, it is not intended to limit the present invention. A person with ordinary knowledge in the technical field to which the present invention belongs may make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention shall be determined by the definition of the claims.

Claims

1. A variable frequency electric field generating system, characterized in that: include: An alternating power generator (100), the alternating power generator (100) being used to generate a sinusoidal wave signal, the sinusoidal wave signal having a frequency of 500-1500 kHz and an amplitude of 50-100 Vpp; A wire (300), a first end of which is connected to an output end of the alternating power generator (100); At least one pair of insulated electrode plates (200) connected to the second end of the wire (300); The insulating electrode plate (200) comprises a flexible conductive layer and a flexible insulating layer coated on both sides of the flexible conductive layer, and the insulating electrode plate (200) is applied to the surface of the diseased part of the body, or applied as an implant to the surface of the diseased internal organs; When the alternating power generator (100) outputs a sine wave signal to the insulating electrode plate (200), its rated output power is less than 3W, and the alternating electric field generated between a pair of the insulating electrode plates (200) is used to inhibit the generation of angiogenic growth factors in the alternating electric field region.

2. The variable frequency electric field generating system according to claim 1, characterized in that: The spacing between the pair of insulating electrode plates (200) and the amplitude of the alternating power generator (100) are configured to ensure that the intensity of the alternating electric field generated between the pair of insulating electrode plates (200) is greater than 0.6 V / cm.

3. The variable frequency electric field generating system according to claim 1, characterized in that: The flexible conductive layer comprises a metal layer (202), and the metal layer (202) comprises a silver foil layer.

4. The variable frequency electric field generating system according to claim 1, characterized in that: The flexible insulating layer comprises an insulating film (201), and the insulating film (201) comprises a polyimide film.

5. The variable frequency electric field generating system according to claim 3 or 4, characterized in that: The thickness of the flexible conductive layer and the flexible insulating layer is less than 0.1 mm.

6. The variable frequency electric field generating system according to claim 1, characterized in that: The frequency of the sine wave signal is 800-1200 kHz.

7. The variable frequency electric field generating system according to any one of claims 1 to 6, characterized in that: The frequency of the sine wave signal is 1000 kHz.

8. The variable frequency electric field generating system according to claim 1, characterized in that: The alternating current power generator (100) comprises a sine wave generator (1), a differential amplifier (2), a step-up transformer (3), a communication controller (4) and a DC / DC isolated voltage-stabilized power supply (5); the sine wave generator (1), the differential amplifier (2) and the step-up transformer (3) are connected in sequence; the communication controller (4) is connected to the sine wave generator (1); and the DC / DC isolated voltage-stabilized power supply (5) provides power for various components.

9. The variable frequency electric field generating system according to claim 8, characterized in that: The sine wave generator adopts a high-frequency waveform generator of an integrated chip MAX038.

10. Use of a variable frequency electric field generating system as claimed in any one of claims 1 to 9 in the treatment of pathological angiogenesis.

Citation Information

Patent Citations

  • Method and device for inhibiting rapid growth of tumor cells by using sensitive frequency electric field

    CN112553075A

  • Electric field generating device and control method thereof

    CN113599703A

  • High frequency ac power inverter circuit

    CN207732652U

  • Brain tumor field intensity detection instrument based on TTFields electric field

    CN217162096U

  • Apparatus for destroying dividing cells

    US20040068295A1